<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03938545</url>
  </required_header>
  <id_info>
    <org_study_id>RVT-1401-2001</org_study_id>
    <nct_id>NCT03938545</nct_id>
  </id_info>
  <brief_title>ASCEND GO-2: Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )</brief_title>
  <official_title>ASCEND GO-2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients With Active, Moderate to Severe Graves' Ophthalmopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immunovant Sciences GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Immunovant Sciences GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the current study is to assess the efficacy and safety/tolerability of three&#xD;
      dose regimens of RVT-1401 in the treatment of active, moderate to severe GO patients. In&#xD;
      addition, the study is designed to characterize the effect of RVT-1401 exposure on reduction&#xD;
      in anti-TSHR IgG&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision based on premature unblinding of treatment allocations necessitated by&#xD;
    program-wide review&#xD;
  </why_stopped>
  <start_date type="Actual">July 23, 2019</start_date>
  <completion_date type="Actual">April 15, 2021</completion_date>
  <primary_completion_date type="Actual">February 2, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of safety by analysis of adverse events (AEs) data</measure>
    <time_frame>13 weeks</time_frame>
    <description>AE summaries of the number and percent of participants reporting each event at least once will be generated. Other safety data will be summarized descriptively.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of proptosis responders in study eye without deterioration in fellow eye at the end of treatment</measure>
    <time_frame>13 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proptosis responder rate</measure>
    <time_frame>Weeks 1-12, weeks 14-20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in proptosis</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Activity Score (CAS)</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with overall ophthalmic improvement</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Gorman Score for diplopia</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Graves' Ophthalmopathy Quality of Life (GO-QOL)</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with Clinical Activity Score (CAS) of 0 or 1</measure>
    <time_frame>20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Graves' Ophthalmopathy (GO)</condition>
  <arm_group>
    <arm_group_label>Regimen A-RVT-1401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen A= RVT-1401 680 mg weekly for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B-RVT-1401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen B= RVT-1401 340 mg weekly for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen C-RVT-1401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regimen C= RVT-1401 255 mg weekly for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RVT-1401 (Administered via subcutaneous injection)</intervention_name>
    <description>RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.</description>
    <arm_group_label>Regimen A-RVT-1401</arm_group_label>
    <arm_group_label>Regimen B-RVT-1401</arm_group_label>
    <arm_group_label>Regimen C-RVT-1401</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo (Administered via subcutaneous injection)</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥ 18 years of age.&#xD;
&#xD;
          2. Clinical diagnosis of Graves' disease with hyperthyroidism associated with active,&#xD;
             moderate to severe GO with a Clinical Activity Score (CAS) ≥ 4 for the most severely&#xD;
             affected eye at Screening and Baseline (on the 7-item scale).&#xD;
&#xD;
          3. Onset of active GO within 9 months of screening.&#xD;
&#xD;
          4. Moderate-to-severe active GO (not sight-threatening but has an appreciable impact on&#xD;
             daily life), usually associated with one or more of the following: lid retraction ≥ 2&#xD;
             mm, moderate or severe soft tissue involvement, proptosis ≥ 3 mm above normal for race&#xD;
             and gender, and/or inconstant or constant diplopia.&#xD;
&#xD;
          5. Other, more specific inclusion criteria are defined in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any steroid (IV, oral, steroid eye drops) for the treatment of GO or other&#xD;
             conditions within 3 weeks prior to Screening. Steroids cannot be initiated during the&#xD;
             trial. Exceptions include topical and inhaled steroids which are allowed.&#xD;
&#xD;
          2. Use of rituximab, tocilizumab, or any monoclonal antibody for immunomodulation within&#xD;
             the past 9 months prior to Baseline.&#xD;
&#xD;
          3. Total IgG level &lt; 6g/L at Screening.&#xD;
&#xD;
          4. Absolute neutrophil count &lt;1500 cells/mm3 at Screening.&#xD;
&#xD;
          5. Participants with decreased best corrected visual acuity due to optic neuropathy as&#xD;
             defined by a decrease in vision of 2 lines on the Snellen chart, new visual field&#xD;
             defect, or color defect secondary to optic nerve involvement within the last 6 months&#xD;
             at Screening.&#xD;
&#xD;
          6. Previous orbital irradiation or surgery for GO.&#xD;
&#xD;
          7. Other, more specific exclusion criteria are defined in the protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Multispecialty Aesthetic Clinical Research Organziation (MACRO)</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doheny Eye Center UCLA</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals &amp; Clinics - Eye Clinic</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan - Kellogg Eye Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine - Center for Advanced Medicine (CAM) - Eye Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University (OHSU) - Casey Eye Institute (CEI)-Marquam Hill</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Wellness Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eyelid Center of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Eye Institute</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z-1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Retina Institute</name>
      <address>
        <city>North York</city>
        <state>Ontario</state>
        <zip>M3C 0G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Eye Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology University Center- Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitat Duisburg-Essen</name>
      <address>
        <city>Duisburg</city>
        <zip>47057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orbitazentrum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60318</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARNAS Garibaldi, Presidio di Nesima</name>
      <address>
        <city>Palermo</city>
        <state>Catania</state>
        <zip>95122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unità Operativa di Endocrinologia 2, Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Oftalmologia Barraquer</name>
      <address>
        <city>Barcelona</city>
        <zip>08021</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 1, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>May 31, 2021</last_update_submitted>
  <last_update_submitted_qc>May 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IMVT-1401</keyword>
  <keyword>Graves' Orbitopathy</keyword>
  <keyword>Thyroid Eye Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

